3 months ago
KRYS
AnalystsRitu BaralRitu Baral's Stock Forecasts
AnalystsRitu Baral
Analyst Ranking
Top 31%
#1638 out of 5235 analysts
Average Return
+1.12%
Win Rate
36%16 out of 44
Risk vs Reward
Poor
Good
Ritu Baral's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Palvella Therapeutics IncPVLA | +455.62% | $14.76 | $82.01 | 2025-02-05 - 2026-02-04 | Strong Buy |
Alnylam Pharmaceuticals IncALNY | +68.22% | $292.01 | $491.22 | 2024-10-21 - 2025-10-20 | Strong Buy |
Acadia Pharmaceuticals IncACAD | +61.25% | $16.62 | $26.80 | 2022-08-08 - 2023-08-07 | Buy |
Palvella Therapeutics IncPVLA | +57.01% | $78.63 | $123.46 | 2025-11-06 - 2026-04-02 | Strong Buy |
Insmed IncINSM | +48.08% | $73.98 | $109.55 | 2024-08-09 - 2025-08-08 | Strong Buy |
Ritu Baral Analyst Color
Get additional color on Ritu Baral's coverage of popular stocks
4 months ago
PVLA
4 months ago
INSM
4 months ago
PRAX
4 months ago
VERA
5 months ago
INSM
3 years ago
SAGE
Ritu Baral's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Terns Pharmaceuticals IncTERN | 2 | Hold | $53.00 | +0.53% | Downgrades | 10 days ago |
Acadia Pharmaceuticals IncACAD | 3 | Strong Buy | $37.00 | +66.67% | Maintains | a month ago |
Krystal Biotech IncKRYS | 1 | Strong Buy | $306.00 | +17.26% | Maintains | 3 months ago |
Vtv Therapeutics IncVTVT | 1 | Strong Buy | $67.00 | +62.74% | Initiates Coverage On | 3 months ago |
Insmed IncINSM | 7 | Strong Buy | $241.00 | +48.37% | Maintains | 4 months ago |
Palvella Therapeutics IncPVLA | 3 | Strong Buy | $133.00 | +7.73% | Maintains | 4 months ago |
Milestone Pharmaceuticals IncMIST | 1 | Strong Buy | $8.00 | +479.71% | Upgrades | 4 months ago |
Praxis Precision Medicines IncPRAX | 1 | Strong Buy | $353.00 | +13.73% | Maintains | 4 months ago |
Vera Therapeutics IncVERA | 2 | Strong Buy | $73.00 | +78.66% | Maintains | 4 months ago |
Avidity Biosciences IncRNAM | 2 | Hold | $74.00 | +401.69% | Downgrades | 5 months ago |
Madrigal Pharmaceuticals IncMDGL | 2 | Strong Buy | $554.00 | +1.30% | Maintains | 7 months ago |
Akero Therapeutics IncAKRO | 1 | Strong Buy | $76.00 | +39.07% | Initiates Coverage On | 8 months ago |
Sage Therapeutics IncSAGE | 6 | Hold | $9.00 | N/A | Maintains | a year ago |
Alnylam Pharmaceuticals IncALNY | 3 | Strong Buy | $371.00 | N/A | Maintains | a year ago |
Ngm Biopharmaceuticals IncNGM | 2 | Hold | $1.55 | N/A | Downgrades | 2 years ago |
Sarepta Therapeutics IncSRPT | 1 | Buy | $175.00 | N/A | Maintains | 3 years ago |
Albireo Pharma IncALBO | 2 | Hold | $48.00 | N/A | Downgrades | 3 years ago |
Aptinyx IncAPTX | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Global Blood Therapeutics IncGBT | 2 | Hold | $68.50 | N/A | Downgrades | 4 years ago |
Spero Therapeutics IncSPRO | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
An2 Therapeutics IncANTX | 1 | Buy | N/A | N/A | Initiates Coverage On | 4 years ago |
Spruce Biosciences IncSPRB | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Rallybio CorpRLYB | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Gh Research PLCGHRS | 1 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Ataibeckley IncATAI | 2 | Buy | N/A | N/A | Initiates Coverage On | 5 years ago |
Myokardia IncMYOK | 1 | Hold | $225.00 | N/A | Downgrades | 5 years ago |
Intercept Pharmaceuticals IncICPT | 1 | Hold | $47.00 | N/A | Downgrades | 6 years ago |
Pliant Therapeutics IncPLRX | 1 | Buy | N/A | N/A | Initiates Coverage On | 6 years ago |
Orchard Therapeutics PLCORTX | 1 | Buy | $270.00 | N/A | Initiates Coverage On | 7 years ago |
Axon Enterprise IncAXON | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Allena Pharmaceuticals IncALNAQ | 1 | Buy | N/A | N/A | Initiates Coverage On | 8 years ago |
Trean Insurance Group IncTIG | 1 | Buy | N/A | N/A | Initiates Coverage On | 9 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.